



Clinical trial results:

An Open-label, Single-dose, Pharmacokinetic Study to Evaluate IV Eptinezumab in Children and Adolescents with Migraine, Followed by an Optional, Multiple-dose, Open-label Extension Period

Summary

| | |
|--------------------------|----------------|
| EudraCT number | 2022-004102-29 |
| Trial protocol | Outside EU/EEA |
| Global end of trial date | |

Results information

| | |
|--------------------------------|---------------|
| Result version number | v1 |
| This version publication date | 15 April 2023 |
| First version publication date | 15 April 2023 |

Trial information

Trial identification

| | |
|-----------------------|--------|
| Sponsor protocol code | 18922A |
|-----------------------|--------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT04537429 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | H. Lundbeck A/S |
| Sponsor organisation address | Ottiliavej 9, Valby, Denmark, 2500 |
| Public contact | LundbeckClinicalTrials@lundbeck.com, H. Lundbeck A/S, +45 36301311, LundbeckClinicalTrials@lundbeck.com |
| Scientific contact | LundbeckClinicalTrials@lundbeck.com, H. Lundbeck A/S, +45 36301311, LundbeckClinicalTrials@lundbeck.com |

Notes:

Paediatric regulatory details

| | |
|--|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-002243-PIP01-17 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | Yes |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Interim |
| Date of interim/final analysis | 20 October 2022 |
| Is this the analysis of the primary completion data? | Yes |
| Primary completion date | 20 October 2022 |
| Global end of trial reached? | No |

Notes:

General information about the trial

Main objective of the trial:

The main objective of the trial is to characterize the pharmacokinetics (PK) profile of eptinezumab after a single intravenous (IV) administration in pediatric participants 6 to 17 years of age.

Protection of trial subjects:

This study is being conducted in compliance with Good Clinical Practice and in accordance with the ethical principles described in the Declaration of Helsinki.

Background therapy: -

Evidence for comparator: -

| | |
|---|----------------|
| Actual start date of recruitment | 04 August 2020 |
| Long term follow-up planned | No |
| Independent data monitoring committee (IDMC) involvement? | Yes |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|-------------------|
| Country: Number of subjects enrolled | United States: 28 |
| Worldwide total number of subjects | 28 |
| EEA total number of subjects | 0 |

Notes:

Subjects enrolled per age group

| | |
|---|----|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |
| Infants and toddlers (28 days-23 months) | 0 |
| Children (2-11 years) | 12 |
| Adolescents (12-17 years) | 16 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

The study consists of a single-dose, 20-week Main Study Period (Part A) and an optional 44-week multiple-dose Extension Period (Part B). The data collected during the completed Main Study Period (Part A) are presented. The data from the ongoing Extension Period (Part B) will be presented when the study has been completed.

Period 1

| | |
|------------------------------|--------------------------------|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Not applicable |
| Blinding used | Not blinded |

Arms

| | |
|------------------------------|---------------------------------------|
| Are arms mutually exclusive? | Yes |
| Arm title | Eptinezumab (Age Group 6 to 11 Years) |

Arm description:

Participants received a single dose of eptinezumab on Day 1 based on the highest target adult exposure of eptinezumab, adjusted for the participant's body weight.

| | |
|--|---------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Eptinezumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Eptinezumab will be administered per schedule specified in the arm description.

| | |
|------------------|--|
| Arm title | Eptinezumab (Age Group 12 to 17 Years) |
|------------------|--|

Arm description:

Participants received a single dose of eptinezumab on Day 1 based on the highest target adult exposure of eptinezumab, adjusted for the participant's body weight.

| | |
|--|---------------------------------------|
| Arm type | Experimental |
| Investigational medicinal product name | Eptinezumab |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Concentrate for solution for infusion |
| Routes of administration | Intravenous use |

Dosage and administration details:

Eptinezumab will be administered per schedule specified in the arm description.

| Number of subjects in period 1 | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) |
|--|--|---|
| Started | 12 | 16 |
| Received at least 1 dose of study drug | 12 | 16 |
| Completed | 11 | 14 |
| Not completed | 1 | 2 |
| Consent withdrawn by subject | 1 | - |
| Other than specified | - | 1 |
| Lost to follow-up | - | 1 |

Baseline characteristics

Reporting groups

| | |
|-----------------------|---------------------------------------|
| Reporting group title | Eptinezumab (Age Group 6 to 11 Years) |
|-----------------------|---------------------------------------|

Reporting group description:

Participants received a single dose of eptinezumab on Day 1 based on the highest target adult exposure of eptinezumab, adjusted for the participant's body weight.

| | |
|-----------------------|--|
| Reporting group title | Eptinezumab (Age Group 12 to 17 Years) |
|-----------------------|--|

Reporting group description:

Participants received a single dose of eptinezumab on Day 1 based on the highest target adult exposure of eptinezumab, adjusted for the participant's body weight.

| Reporting group values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | Total |
|---------------------------------------|---------------------------------------|--|-------|
| Number of subjects | 12 | 16 | 28 |
| Age Categorical Units: Subjects | | | |
| Children (2-11 years) | 12 | 0 | 12 |
| Adolescents (12-17 years) | 0 | 16 | 16 |
| Age Continuous Units: years | | | |
| arithmetic mean | 9.3 | 15.1 | |
| standard deviation | ± 1.97 | ± 1.41 | - |
| Gender Categorical Units: Subjects | | | |
| Female | 10 | 10 | 20 |
| Male | 2 | 6 | 8 |
| Ethnicity Units: Subjects | | | |
| Hispanic or Latino | 1 | 5 | 6 |
| Not Hispanic or Latino | 11 | 11 | 22 |
| Race Units: Subjects | | | |
| Asian | 1 | 0 | 1 |
| Black or African American | 1 | 1 | 2 |
| White or Caucasian | 9 | 15 | 24 |
| Other | 1 | 0 | 1 |

End points

End points reporting groups

| | |
|--|--|
| Reporting group title | Eptinezumab (Age Group 6 to 11 Years) |
| Reporting group description: Participants received a single dose of eptinezumab on Day 1 based on the highest target adult exposure of eptinezumab, adjusted for the participant's body weight. | |
| Reporting group title | Eptinezumab (Age Group 12 to 17 Years) |
| Reporting group description: Participants received a single dose of eptinezumab on Day 1 based on the highest target adult exposure of eptinezumab, adjusted for the participant's body weight. | |

Primary: Part A: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Eptinezumab

| | |
|--|--|
| End point title | Part A: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC0-inf) of Eptinezumab ^[1] |
| End point description: PK Part A set (PKS_A) included all treated participants in Part A with at least 1 post-infusion PK sample in Part A. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint. n = participants evaluable for specified category. '99999' signifies 'data not available since no participants were evaluable in that category'. '9999' signifies 'due to single participant, geometric coefficient of variation data could not be calculated'. | |
| End point type | Primary |
| End point timeframe: Day 1 (the day of infusion) through Week 20 | |

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The statistical analysis was not planned for this endpoint.

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|---|---------------------------------------|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 15 | | |
| Units: hours*micrograms (µg)/milliliter (mL) | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Weight Group >20 kg - <=40 kg (n=10,0) | 87780 (± 33.1) | 99999 (± 99999) | | |
| Weight Group >40 kg (n=1,15) | 141700 (± 9999) | 91520 (± 15.1) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Part A: Maximum Observed Plasma Concentration (Cmax) of Eptinezumab

| | |
|-----------------|--|
| End point title | Part A: Maximum Observed Plasma Concentration (Cmax) of Eptinezumab ^[2] |
|-----------------|--|

End point description:

PKS_A included all treated participants in Part A with at least 1 post-infusion PK sample in Part A. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint. n = participants evaluable for specified category. '99999' signifies 'data not available since no participants were evaluable in that category'. '9999' signifies 'due to single participant, geometric coefficient of variation data could not be calculated'.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Day 1 (the day of infusion) through Week 20

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The statistical analysis was not planned for this endpoint.

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|--|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 11 | 16 | | |
| Units: µg/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Weight Group >20 kg - <=40 kg (n=11,0) | 126.2 (± 31.9) | 99999 (± 99999) | | |
| Weight Group >40 kg (n=1,16) | 215.7 (± 9999) | 129.7 (± 32.4) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Area Under the Concentration Versus Time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC0-t last) of Eptinezumab

| | |
|-----------------|---|
| End point title | Part A: Area Under the Concentration Versus Time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUC0-t last) of Eptinezumab |
|-----------------|---|

End point description:

PKS_A included all treated participants in Part A with at least 1 post-infusion PK sample in Part A. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint. n = participants evaluable for specified category. '99999' signifies 'data not available since no participants were evaluable in that category'. '9999' signifies 'due to single participant, geometric coefficient of variation data could not be calculated'.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Day 1 (the day of infusion) through Week 20

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|--|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 11 | 16 | | |
| Units: hours*µg/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Weight Group >20 kg - <=40 kg (n=11,0) | 79260 (± 40.6) | 99999 (± 99999) | | |
| Weight Group >40 kg (n=1,16) | 138000 (± 9999) | 86500 (± 15.4) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Concentration for Eptinezumab Determined From the Data Without Interpolation at Week 12 (C12wk)

| | |
|--|---|
| End point title | Part A: Concentration for Eptinezumab Determined From the Data Without Interpolation at Week 12 (C12wk) |
| End point description: | |
| PKS_A included all treated participants in Part A with at least 1 post-infusion PK sample in Part A. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint. n = participants evaluable for specified category. '99999' signifies 'data not available since no participants were evaluable in that category'. '9999' signifies 'due to single participant, geometric coefficient of variation data could not be calculated'. | |
| End point type | Secondary |
| End point timeframe: | |
| Week 12 | |

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|--|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 15 | | |
| Units: µg/mL | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Weight Group >20 kg - <=40 kg (n=10,0) | 6.440 (± 117) | 99999 (± 99999) | | |
| Weight Group >40 kg (n=1,15) | 13.38 (± 9999) | 9.502 (± 28.5) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Time to Reach Cmax (tmax) of Eptinezumab

| | |
|---|--|
| End point title | Part A: Time to Reach Cmax (tmax) of Eptinezumab |
| End point description: PKS_A included all treated participants in Part A with at least 1 post-infusion PK sample in Part A. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint. n = participants evaluable for specified category. '99999' signifies 'data not available since no participants were evaluable in that category'. | |
| End point type | Secondary |
| End point timeframe: Day 1 (the day of infusion) through Week 20 | |

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|---|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 11 | 16 | | |
| Units: hours | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| Weight Group >20 kg - <=40 kg (n=11,0) | 0.6830 (0.5830 to 2.500) | 99999 (99999 to 99999) | | |
| Weight Group >40 kg (n=1,16) | 2.617 (2.617 to 2.617) | 1.708 (0.6165 to 2.675) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Terminal Elimination Half-life (t1/2) of Eptinezumab

| | |
|---|--|
| End point title | Part A: Terminal Elimination Half-life (t1/2) of Eptinezumab |
| End point description: PKS_A included all treated participants in Part A with at least 1 post-infusion PK sample in Part A. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint. n = participants evaluable for specified category. '99999' signifies 'data not available since no participants were evaluable in that category'. | |
| End point type | Secondary |
| End point timeframe: Day 1 (the day of infusion) through Week 20 | |

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|---|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 15 | | |
| Units: hours | | | | |
| median (inter-quartile range (Q1-Q3)) | | | | |
| Weight Group >20 kg - <=40 kg (n=10,0) | 659.5 (584.5 to 729.9) | 99999 (99999 to 99999) | | |

| | | | | |
|------------------------------|------------------------|------------------------|--|--|
| Weight Group >40 kg (n=1,15) | 697.3 (697.3 to 697.3) | 702.4 (609.2 to 800.0) | | |
|------------------------------|------------------------|------------------------|--|--|

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Plasma Clearance (CL) of Eptinezumab

| | |
|--|--|
| End point title | Part A: Plasma Clearance (CL) of Eptinezumab |
| End point description: PKS_A included all treated participants in Part A with at least 1 post-infusion PK sample in Part A. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint. n = participants evaluable for specified category. '99999' signifies 'data not available since no participants were evaluable in that category'. '9999' signifies 'due to single participant, geometric coefficient of variation data could not be calculated'. | |
| End point type | Secondary |
| End point timeframe: Day 1 (the day of infusion) through Week 20 | |

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|---|---------------------------------------|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 15 | | |
| Units: liters/hour | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Weight Group >20 kg - <=40 kg (n=10,0) | 0.001709 (± 33.1) | 99999 (± 99999) | | |
| Weight Group >40 kg (n=1,15) | 0.002118 (± 9999) | 0.003278 (± 15.1) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Volume of Distribution (Vz) of Eptinezumab

| | |
|--|--|
| End point title | Part A: Volume of Distribution (Vz) of Eptinezumab |
| End point description: PKS_A included all treated participants in Part A with at least 1 post-infusion PK sample in Part A. Here, 'Overall number of participants analyzed' = participants evaluable for this endpoint. n = participants evaluable for specified category. '99999' signifies 'data not available since no participants were evaluable in that category'. '9999' signifies 'due to single participant, geometric coefficient of variation data could not be calculated'. | |
| End point type | Secondary |

End point timeframe:

Day 1 (the day of infusion) through Week 20

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|--|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 10 | 15 | | |
| Units: liters | | | | |
| geometric mean (geometric coefficient of variation) | | | | |
| Weight Group >20 kg - <=40 kg (n=10,0) | 1.591 (± 33.7) | 99999 (± 99999) | | |
| Weight Group >40 kg (n=1,15) | 2.130 (± 9999) | 3.324 (± 25.2) | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Number of Participants With Binding Anti-Drug Antibodies (ADAs)

| | |
|-----------------|---|
| End point title | Part A: Number of Participants With Binding Anti-Drug Antibodies (ADAs) |
|-----------------|---|

End point description:

Number of participants with positive ADAs are reported. All-patients-treated in Part A set (APTS_A) included all participants treated with eptinezumab in Part A. Here, 'overall number of participants analyzed' = participants evaluable for this endpoint.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

Week 20

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 11 | 14 | | |
| Units: participants | 0 | 2 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Part A: Number of Participants With Neutralizing Binding ADA (NAb)

| | |
|-----------------|--|
| End point title | Part A: Number of Participants With Neutralizing Binding ADA |
|-----------------|--|

| |
|-------|
| (NAb) |
|-------|

End point description:

Number of participants with non-reactive NABs are reported. APTS_A included all participants treated with eptinezumab in Part A. Here, 'overall number of participants analyzed' = participants evaluable for this endpoint.

End point type

Secondary

End point timeframe:

Week 20

| End point values | Eptinezumab (Age Group 6 to 11 Years) | Eptinezumab (Age Group 12 to 17 Years) | | |
|-----------------------------|---|--|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 11 | 14 | | |
| Units: participants | 0 | 2 | | |

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Baseline up to Week 20

Adverse event reporting additional description:

APTS_A included all participants treated with eptinezumab in Part A.

| | |
|-----------------|------------|
| Assessment type | Systematic |
|-----------------|------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 24.0 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|--|
| Reporting group title | Eptinezumab (Age Group 12 to 17 Years) |
|-----------------------|--|

Reporting group description:

Participants received a single dose of eptinezumab on Day 1 based on the highest target adult exposure of eptinezumab, adjusted for the participant's body weight.

| | |
|-----------------------|---------------------------------------|
| Reporting group title | Eptinezumab (Age Group 6 to 11 Years) |
|-----------------------|---------------------------------------|

Reporting group description:

Participants received a single dose of eptinezumab on Day 1 based on the highest target adult exposure of eptinezumab, adjusted for the participant's body weight.

| Serious adverse events | Eptinezumab (Age Group 12 to 17 Years) | Eptinezumab (Age Group 6 to 11 Years) | |
|---|--|---------------------------------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 0 / 16 (0.00%) | 0 / 12 (0.00%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | | | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | Eptinezumab (Age Group 12 to 17 Years) | Eptinezumab (Age Group 6 to 11 Years) | |
|---|--|---------------------------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 9 / 16 (56.25%) | 7 / 12 (58.33%) | |
| Investigations | | | |
| Blood calcium increased | | | |
| alternative assessment type: Non-systematic | | | |
| subjects affected / exposed | 1 / 16 (6.25%) | 0 / 12 (0.00%) | |
| occurrences (all) | 1 | 0 | |
| Weight increased | | | |

| | | | |
|---|--|--|--|
| alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 1 / 16 (6.25%) 1 | 0 / 12 (0.00%) 0 | |
| Injury, poisoning and procedural complications Accidental overdose alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Vascular disorders Orthostatic hypotension alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 3 / 16 (18.75%) 4 | 0 / 12 (0.00%) 0 | |
| Nervous system disorders Migraine alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) Dizziness alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 1 / 16 (6.25%) 1 | 1 / 12 (8.33%) 1 0 / 12 (0.00%) 0 | |
| Blood and lymphatic system disorders Iron deficiency anaemia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Eye disorders Photopsia alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Respiratory, thoracic and mediastinal disorders Rhinorrhoea alternative assessment type: Non-systematic | | | |

| | | | |
|--|--|--|--|
| <p>subjects affected / exposed</p> <p>0 / 16 (0.00%)</p> <p>1 / 12 (8.33%)</p> <p>occurrences (all)</p> <p>0</p> <p>1</p> <p>Epistaxis</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 16 (6.25%)</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>0</p> <p>Cough</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>0 / 16 (0.00%)</p> <p>1 / 12 (8.33%)</p> <p>occurrences (all)</p> <p>0</p> <p>1</p> | | | |
| <p>Skin and subcutaneous tissue disorders</p> <p>Pruritus</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 16 (6.25%)</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>0</p> | | | |
| <p>Psychiatric disorders</p> <p>Depression</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>0 / 16 (0.00%)</p> <p>1 / 12 (8.33%)</p> <p>occurrences (all)</p> <p>0</p> <p>1</p> <p>Anxiety</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>0 / 16 (0.00%)</p> <p>1 / 12 (8.33%)</p> <p>occurrences (all)</p> <p>0</p> <p>1</p> <p>Adjustment disorder with depressed mood</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>1 / 16 (6.25%)</p> <p>0 / 12 (0.00%)</p> <p>occurrences (all)</p> <p>1</p> <p>0</p> <p>Sleep terror</p> <p>alternative assessment type: Non-systematic</p> <p>subjects affected / exposed</p> <p>0 / 16 (0.00%)</p> <p>1 / 12 (8.33%)</p> <p>occurrences (all)</p> <p>0</p> <p>1</p> | | | |
| Renal and urinary disorders | | | |

| | | | |
|---|---------------------|---------------------|--|
| Proteinuria alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Infections and infestations COVID-19 alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Gastroenteritis viral alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Influenza alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 1 / 16 (6.25%) 1 | 0 / 12 (0.00%) 0 | |
| Pharyngitis streptococcal alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Pyuria alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Urinary tract infection alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 0 / 16 (0.00%) 0 | 1 / 12 (8.33%) 1 | |
| Metabolism and nutrition disorders Vitamin D deficiency alternative assessment type: Non-systematic subjects affected / exposed occurrences (all) | 1 / 16 (6.25%) 1 | 0 / 12 (0.00%) 0 | |
| Hypertriglyceridaemia | | | |

| | | | |
|---|----------------|----------------|--|
| alternative assessment type: Non-systematic | | | |
| subjects affected / exposed | 0 / 16 (0.00%) | 1 / 12 (8.33%) | |
| occurrences (all) | 0 | 1 | |
| Vitamin B12 deficiency | | | |
| alternative assessment type: Non-systematic | | | |
| subjects affected / exposed | 1 / 16 (6.25%) | 0 / 12 (0.00%) | |
| occurrences (all) | 1 | 0 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|------------------|---|
| 20 November 2020 | <ul style="list-style-type: none">- Added the eDiary and in consequence, added 2 exploratory endpoints related to the eDiary and updated the screening period to 4 weeks.- Inclusion criterion: upper percentile limit of Centers for Disease Control and Prevention growth charts changed from 95th to 97th percentile.- Inclusion criterion: specification of adequate method of contraception.- Added description of potential mitigations due to COVID-19 pandemic.- Added that re-screening of participants for other reasons than safety concerns may be granted.- Updated that use of acute medication was allowed if dose had been stable for ≥ 2 weeks; minimum required period prior to screening visits reduced from ≥ 12 to ≥ 2 weeks. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported